Plain-English translation of NCT03715933 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This is one of the first times this treatment has been tested in people.
This is an early-stage study testing a new medication called , which is a specially designed antibody that works by activating a natural death pathway in cancer cells. Researchers are trying to find the right dose and see if this treatment works for people with advanced solid tumors, including sarcomas, mesothelioma, gastric cancer, and colorectal cancer.
Currently, many people with advanced cancers have limited treatment options, especially when cancer has spread or come back after other therapies. This medication targets a specific pathway that may help the body's immune system kill cancer cells more effectively.
You likely qualify if…
You likely don't qualify if…
Participants will visit the study center regularly to receive the medication as an infusion and have blood work and imaging tests to monitor how the cancer responds and how their body tolerates the treatment. The study has different phases: first, researchers slowly increase the dose to find the safest level, then larger groups receive the medication at that dose to confirm it works. Participation involves ongoing visits and monitoring for as long as the treatment is working and safe.
AI-generated summary from trial data · Jun 3, 2026 · Not medical advice
United States